Education
About Us
Working with TipRanks
Follow Us
Grifols SA (GRFS)
NASDAQ:GRFS
GRFS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.79 - $9.96
Previous CloseN/A
Volume119.87K
Average Volume (3M)729.88K
Market Cap
$7.41B
Enterprise Value$14.59B
Total Cash (Recent Filing)$1.00B
Total Debt (Recent Filing)€10.09B
Price to Earnings (P/E)29.1
Beta1.05
Next Earnings
Jul 24, 2025EPS Estimate
0.22Last Dividend Ex-Date
Jun 03, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding261,425,100
10 Day Avg. Volume673,625
30 Day Avg. Volume729,877
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)0.88
Price to Sales (P/S)0.00
P/FCF Ratio-13.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Grifols SA News
PremiumCompany Announcements
Grifols Completes Acquisition of Biotest Shares Following Delisting
PremiumCompany Announcements
Grifols SA Reports Strong Q1 2025 Financial Performance
PremiumCompany Announcements
Grifols SA Reports Strong Q1 2025 Earnings
PremiumPre-Earnings
Grifols SA (GRFS) Q1 Earnings Cheat SheetOwnership Overview
―
Insiders
8.52% Mutual Funds
41.15% Other Institutional Investors
49.34% Public Companies and Individual Investors
GRFS FAQ
What was Grifols SA’s price range in the past 12 months?
Grifols SA lowest stock price was $5.79 and its highest was $9.96 in the past 12 months.
What is Grifols SA’s market cap?
Grifols SA’s market cap is $7.41B.
When is Grifols SA’s upcoming earnings report date?
Grifols SA’s upcoming earnings report date is Jul 24, 2025 which is in 42 days.
How were Grifols SA’s earnings last quarter?
Grifols SA released its earnings results on May 12, 2025. The company reported $0.092 earnings per share for the quarter, missing the consensus estimate of $0.149 by -$0.057.
Is Grifols SA overvalued?
According to Wall Street analysts Grifols SA’s price is currently Overvalued.
Does Grifols SA pay dividends?
Grifols SA pays a Annually dividend of $0.345 which represents an annual dividend yield of N/A. See more information on Grifols SA dividends here
What is Grifols SA’s EPS estimate?
Grifols SA’s EPS estimate is 0.22.
How many shares outstanding does Grifols SA have?
Grifols SA has 261,425,100 shares outstanding.
What happened to Grifols SA’s price movement after its last earnings report?
Grifols SA reported an EPS of $0.092 in its last earnings report, missing expectations of $0.149. Following the earnings report the stock price went up 8.873%.
Which hedge fund is a major shareholder of Grifols SA?
Currently, no hedge funds are holding shares in GRFS
Grifols SA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GRFS Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 5.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.40%
12-Months-Change
Fundamentals
Return on Equity
3.34%
Trailing 12-Months
Asset Growth
-4.42%
Trailing 12-Months
Company Description
Grifols SA
Grifols SA is a global healthcare company based in Spain, specializing in the production of plasma-derived medicines and transfusion medicine. The company operates through four main divisions: Bioscience, Diagnostic, Hospital, and Bio Supplies. Grifols is a leader in the production of plasma-derived products, which are used to treat a variety of chronic, rare, and often life-threatening conditions. Their product portfolio includes treatments for bleeding disorders, immune deficiencies, and neurological disorders.
GRFS Company Deck
GRFS Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Grifols reported strong Q1 2025 performance with record revenue and growth, particularly in the immunoglobulin franchise. Despite challenges like negative free cash flow due to a strategic payment and temporary albumin issues, the company showed robust adjusted EBITDA and continued deleveraging efforts. The results are ahead of plan even amidst macroeconomic uncertainties and IRA impacts.Read More>